# CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

> **NCT04257175** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CAR-T CD19

## Key facts

- **NCT ID:** NCT04257175
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-18
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04257175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04257175, "CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04257175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*